Seborrheic dermatitis (SD) is a skin condition affecting 2-5% of the global population, with skin microbiome imbalances playing a role in its onset. This research investigated the effects of EUTOPLAC, an oily suspension with Lactobacillus crispatus P17631 and Lacticaseibacillus paracasei I1688, on SD symptoms and the skin's microbial balance. 25 patients underwent a week-long EUTOPLAC treatment. Assessments taken at the baseline, after a week, and three weeks later showed symptom relief and a marked decline in the Malassezia genus. Additionally, a decrease in Staphylococcus and a rise in Lactobacillus and Lacticaseibacillus were observed. The study underscores EUTOPLAC's potential in SD treatment, both in symptom alleviation and microbiome modulation.

Seborrheic dermatitis (SD) affects 2-5% of the global population, with imbalances in the skin microbiome implicated in its development. This study assessed the impact of an oily suspension containing Lactobacillus crispatus P17631 and Lacticaseibacillus paracasei I1688 (termed EUTOPLAC) on SD symptoms and skin microbiome modulation. 25 SD patients were treated with EUTOPLAC for a week. Symptom severity and skin microbiome changes were measured at the start of the treatment (T0), after seven days (T8), and three weeks post-treatment (T28). Results indicated symptom improvement post-EUTOPLAC, with notable reductions in the Malassezia genus. Concurrently, bacterial shifts were observed, including a decrease in Staphylococcus and an increase in Lactobacillus and Lacticaseibacillus. Network analysis highlighted post-EUTOPLAC instability in fungal and bacterial interactions, with increased negative correlations between Malassezia and Lactobacillus and Lacticaseibacillus genera. The study suggests EUTOPLAC's potential as a targeted SD treatment, reducing symptoms and modulating the microbiome composition.